Speaking today (Tuesday 31 October) at the White Rose Bioscience Forum in York, Adams encourages companies to consider both their strengths and weaknesses, and to be open to all potential collaborations to ensure a healthy product portfolio.
“My advice is: be flexible, think out the box; what you can offer as company? Think about what you’ve got, be it technology or know how, and think hard about how you can capitalise on it. The whole company can contribute to this – talk to the research group and ask what else could we do with this technology, or put with this technology, and who could we talk to that they have contacts with? You’ll be surprised how many potential opportunities are generated from this creative brainstorming.”
This advice is based on Antisoma’s own experience. The company does not have a discovery arm; most of what it does is licensed directly from academia or from other biotechs, so it has to be creative in forging the right alliances to create a thriving product pipeline.
“Preclinically our focus is biology and we have enormous expertise in this area,” says Adams. This strength is very attractive to companies whose expertise lies on the chemistry side who have products that need biology.”
Since most cancer therapies around today are derived from plants, Antisoma was very interested to hear from a company contact about a young Australian company, Ecobiotics. Its expertise lay in its knowledge of the different chemical properties of Queensland rainforest plants at various stages of the plants’ growth. Says Adams: “Ecobiotics researchers knew how to select and synthesise the chemicals from various rainforest plants, but lacked the biological expertise, cancer models and in vitro capability.”
Antisoma and Ecobiotics now have a fruitful collaboration underpinned by a simple and transparent agreement.
“No money was exchanged up front and there are no unnecessary legal complexities. They provide us with molecules that display anti-cancer properties, we test them, and all resulting data is shared. Whilst Ecobiotics owns the IP, Antisoma has the right to select up to two molecule classes each year for development. All other test results on other molecules are owned by Ecobiotics which is free to develop the molecule further or offer it to other parties. It’s a perfect solution – they have the chemistry and we have the biology.
"I liken our networking approach to creating a spider’s web down whose strands products can come, whether developed in house, through collaborations or licensed in. The more strands you have the more chance you have of getting products to feed into your pipeline,” he says.
Jo Kelly | alfa
Frugal Innovations: when less is more
19.04.2017 | Fraunhofer-Institut für Arbeitswirtschaft und Organisation IAO
Europe's microtechnology industry is attuned to growth
10.03.2017 | IVAM Fachverband für Mikrotechnik
More and more automobile companies are focusing on body parts made of carbon fiber reinforced plastics (CFRP). However, manufacturing and repair costs must be further reduced in order to make CFRP more economical in use. Together with the Volkswagen AG and five other partners in the project HolQueSt 3D, the Laser Zentrum Hannover e.V. (LZH) has developed laser processes for the automatic trimming, drilling and repair of three-dimensional components.
Automated manufacturing processes are the basis for ultimately establishing the series production of CFRP components. In the project HolQueSt 3D, the LZH has...
Reflecting the structure of composites found in nature and the ancient world, researchers at the University of Illinois at Urbana-Champaign have synthesized thin carbon nanotube (CNT) textiles that exhibit both high electrical conductivity and a level of toughness that is about fifty times higher than copper films, currently used in electronics.
"The structural robustness of thin metal films has significant importance for the reliable operation of smart skin and flexible electronics including...
The nearby, giant radio galaxy M87 hosts a supermassive black hole (BH) and is well-known for its bright jet dominating the spectrum over ten orders of magnitude in frequency. Due to its proximity, jet prominence, and the large black hole mass, M87 is the best laboratory for investigating the formation, acceleration, and collimation of relativistic jets. A research team led by Silke Britzen from the Max Planck Institute for Radio Astronomy in Bonn, Germany, has found strong indication for turbulent processes connecting the accretion disk and the jet of that galaxy providing insights into the longstanding problem of the origin of astrophysical jets.
Supermassive black holes form some of the most enigmatic phenomena in astrophysics. Their enormous energy output is supposed to be generated by the...
The probability to find a certain number of photons inside a laser pulse usually corresponds to a classical distribution of independent events, the so-called...
Microprocessors based on atomically thin materials hold the promise of the evolution of traditional processors as well as new applications in the field of flexible electronics. Now, a TU Wien research team led by Thomas Müller has made a breakthrough in this field as part of an ongoing research project.
Two-dimensional materials, or 2D materials for short, are extremely versatile, although – or often more precisely because – they are made up of just one or a...
20.04.2017 | Event News
18.04.2017 | Event News
03.04.2017 | Event News
27.04.2017 | Life Sciences
27.04.2017 | Physics and Astronomy
27.04.2017 | Earth Sciences